Donald E. Bobo, Jr. Sells 6,000 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 6,000 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $65.30, for a total transaction of $391,800.00. Following the completion of the transaction, the vice president now directly owns 39,503 shares of the company’s stock, valued at $2,579,545.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Edwards Lifesciences Stock Up 1.8 %

EW stock opened at $65.79 on Wednesday. The company has a market cap of $39.90 billion, a PE ratio of 28.12, a price-to-earnings-growth ratio of 3.58 and a beta of 1.02. The business has a 50-day simple moving average of $69.60 and a 200 day simple moving average of $79.97. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $94.87. The company has a quick ratio of 2.45, a current ratio of 3.28 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.59 EPS for the quarter, meeting analysts’ consensus estimates of $0.59. The business had revenue of $1.48 billion during the quarter, compared to the consensus estimate of $1.48 billion. Edwards Lifesciences had a return on equity of 24.54% and a net margin of 24.59%. Edwards Lifesciences’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.61 earnings per share. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the subject of several research reports. Royal Bank of Canada cut their price target on Edwards Lifesciences from $86.00 to $82.00 and set an “outperform” rating for the company in a report on Thursday, October 26th. Oppenheimer raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $90.00 price target for the company in a report on Tuesday, September 26th. StockNews.com downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Tuesday, October 3rd. TheStreet downgraded Edwards Lifesciences from a “b-” rating to a “c+” rating in a report on Wednesday, August 9th. Finally, Stifel Nicolaus cut their price target on Edwards Lifesciences from $87.00 to $70.00 and set a “hold” rating for the company in a report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $84.29.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Advisors Asset Management Inc. grew its position in Edwards Lifesciences by 0.3% in the first quarter. Advisors Asset Management Inc. now owns 43,556 shares of the medical research company’s stock valued at $5,127,000 after acquiring an additional 117 shares during the last quarter. Apollon Wealth Management LLC grew its position in Edwards Lifesciences by 1.0% in the first quarter. Apollon Wealth Management LLC now owns 12,487 shares of the medical research company’s stock valued at $1,033,000 after acquiring an additional 119 shares during the last quarter. Geller Advisors LLC grew its position in Edwards Lifesciences by 6.5% in the first quarter. Geller Advisors LLC now owns 1,965 shares of the medical research company’s stock valued at $231,000 after acquiring an additional 120 shares during the last quarter. Private Trust Co. NA grew its position in Edwards Lifesciences by 1.1% in the second quarter. Private Trust Co. NA now owns 11,410 shares of the medical research company’s stock valued at $1,076,000 after acquiring an additional 125 shares during the last quarter. Finally, Bangor Savings Bank grew its holdings in shares of Edwards Lifesciences by 18.3% during the second quarter. Bangor Savings Bank now owns 839 shares of the medical research company’s stock worth $79,000 after purchasing an additional 130 shares during the last quarter. Institutional investors own 79.25% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.